Atrial Natriuretic Peptide and Parathyroid Hormone (1–84) in Relation to Noradrenaline Induced Changes in Blood Pressure in Uraemic and Healthy Subjects

Abstract

In order to evaluate the hormonal regulation of blood pressure (BP) in uraemia 12 patients on chronic maintenance dialysis and 14 healthy controls were studied. BP and plasma concentrations of atrial natriuretic peptide (ANP), cyclic 3′,5′-guanosine monophosphate (cGMP), and intact parathyroid hormone (PTH(1–84)) were determined before, during, and after a 60 min noradrenaline infusion 0.1 μg kg^-1 body wt. min^-1. Mean BP increased to the same extent in the uraemic patients (median 15 mmHg, range 6–25 mmHg) as in the controls (12 mmHg, 5–25 mmHg). ANP increased during noradrenaline infusion both in patients (7.2 to 8.3 pmol/l, medians, p<0.01) and in controls (4.4 to 6.0 pmol/l, p<0.01), and so did cGMP (patients: 31.6 to 35.9 nmol/l, p<0.05; controls: 6.6 to 8.7 nmol/l, p<0.01). PTH(1–84) was higher in the uraemic patients than in the controls, but was unchanged during noradrenaline infusion in both groups. Correlation analyses gave no evidence of a direct relation between BP and ANP, but basal PTH(1–84) was negatively correlated to basal mean BP in the patients (rho= −0.615, p<0.05), but not in the controls. In conclusion, noradrenaline induced similar elevations of BP in dialysis patients as in healthy controls despite elevated ANP and PTH(1–84) in the patients, and ANP release was stimulated in both groups. PTH(1–84) may participate in blood pressure regulation in uraemic patients.

Key words:

• atrial natriuretic peptide
• blood pressure
• cyclic 3′,5′-guanosine monophosphate
• noradrenaline
• parathyroid hormone
• uraemia